Do you want to read an article? Please log in or register.
Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
Asthma
Related content
Asthma
The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies
Curr Med Res Opin.
Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X
doi: 10.1080/
RECOMMENDED
Asthma
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
Lancet Respir Med.
Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators
doi: 10.1016/S2213-2600
RECOMMENDED
Asthma
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
Eur Respir J.
Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG
doi: 10.1183/13993003.
RECOMMENDED
Asthma
Relationship Between Benralizumab Exposure and Efficacy for Patients with Severe Eosinophilic Asthma
Clin Pharmacol Ther.
Chia YL, Yan L, Yu B, Wang B, Barker P, Goldman M, Roskos L
doi: 10.1002/cpt.
RECOMMENDED
Asthma
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Busse WW, Wenzel SE, Casale TB, FitzGerald JM, Rice MS, Daizadeh N, Deniz Y, Patel N, Harel S, Rowe PJ, Graham NMH, O'Riordan T, Pavord ID
doi: 10.1016/S2213-2600(21)00124-7
Asthma
Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma
Ann Allergy Asthma Immunol.
Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M
doi: 10.1016/j.anai.2018.01.030.
Asthma
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Lancet.
Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M; SIROCCO study investigators
doi: 10.1016/
Asthma
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet.
FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M; CALIMA study investigators
doi: 10.1016/
Asthma
Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials
Front Med.
Liu T, Wang F, Wang G, Mao H
doi: 10.1007/s11684-017-0565-0.